Clinical Efficacy And Safety Studies 'Redundant' For Most Biosimilars
‘Residual Uncertainty’ Surrounding Biosimilars Greatly Reduced Since WHO 2009 Guideline Publication
A team of researchers has concluded that in vivo animal studies and large safety and efficacy studies are rarely necessary to license biosimilars.
